3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
3
Prostatic Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Ovarian Neoplasms
1
Ototoxicity
1
Heart Failure
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Atherosclerosis
1
Interventions
Doxorubicin
15
Cyclophosphamide
9
Exercise
8
Dexrazoxane
8
Razoxane
6
Carvedilol
6
Vincristine
4
Trastuzumab
4
Radiotherapy
4
Filgrastim
4
Docetaxel
4
Methotrexate
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Echocardiography
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Silymarin
2
Prednisone
2
Paclitaxel
2
Neoadjuvant Therapy
2
Leucovorin
2
Ivabradine
2
High-Intensity Interval Training
2
Epirubicin
2
Electrocardiography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cardiotoxicity
×
Hydroxymethylglutaryl-CoA Reductase Inhibitors
×
Clear all
NCT03186404
2022-02-08
SPARE-HF
University Health Network, Toronto
Phase 2
Unknown
112 enrolled